未找到相关数据
Comparison of results from a phase 1/2 study of lumiliximab (Anti-CD23) in combination with FCR for patients with relapsed CLL with published FCR results.
被引：16
作者：
Byrd, John C.
Castro, Januario
O'Brien, Susan
Flinn, Ian W.
Forero-Torres, Andres
Kipps, Thomas J.
Heerema, Nyla A.
Lin, Thomas
Kheoh, Thian
Wynne, Dee
Molina, Arturo
机构：
[1] Ohio State Univ, Arthur James Comprehens Canc Ctr, Columbus, OH 43210 USA
[2] Univ Calif San Diego, Div Hematol Oncol, San Diego, CA 92103 USA
[3] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[5] Univ Alabama, Wallace Tumor Inst, Birmingham, AL USA
[6] Biogen Idec, San Diego, CA USA
来源：
关键词：
D O I：
10.1182/blood.V108.11.32.32
中图分类号：
R5 [内科学];
学科分类号：
1002 [临床医学];
100201 [内科学];
摘要：
32
引用
收藏
页码：14A / 14A
页数：1
相关论文